Q3 EPS Estimates for Kymera Therapeutics Lifted by B. Riley

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at B. Riley boosted their Q3 2025 EPS estimates for shares of Kymera Therapeutics in a research report issued on Tuesday, August 12th. B. Riley analyst M. Mamtani now expects that the company will post earnings of ($0.98) per share for the quarter, up from their prior forecast of ($1.04). B. Riley currently has a “Strong-Buy” rating and a $60.00 target price on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q4 2025 earnings at ($1.09) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.81) EPS and FY2028 earnings at ($5.29) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). The business had revenue of $11.48 million during the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business’s revenue was down 55.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.58) earnings per share.

A number of other brokerages also recently commented on KYMR. Wells Fargo & Company cut their price objective on shares of Kymera Therapeutics from $57.00 to $53.00 and set an “overweight” rating for the company in a research report on Thursday, June 26th. Bank of America upgraded shares of Kymera Therapeutics from a “neutral” rating to a “buy” rating and set a $51.00 price objective for the company in a research report on Monday, June 2nd. Stifel Nicolaus started coverage on shares of Kymera Therapeutics in a research report on Tuesday, May 20th. They set a “buy” rating and a $55.00 price objective for the company. Oppenheimer restated an “outperform” rating and set a $53.00 price objective (down previously from $56.00) on shares of Kymera Therapeutics in a research report on Friday, June 27th. Finally, BTIG Research restated a “buy” rating and set a $59.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $59.11.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $42.63 on Thursday. The firm’s fifty day simple moving average is $44.64 and its 200-day simple moving average is $36.49. The stock has a market capitalization of $3.05 billion, a price-to-earnings ratio of -12.29 and a beta of 2.18. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $53.27.

Insiders Place Their Bets

In related news, Director Jeffrey W. Albers sold 6,349 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $311,101.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Elena Ridloff sold 12,000 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total transaction of $553,200.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,349 shares of company stock valued at $2,334,301. Company insiders own 16.01% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of large investors have recently added to or reduced their stakes in KYMR. Farther Finance Advisors LLC grew its stake in Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after acquiring an additional 540 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares during the last quarter. State of Wyoming acquired a new stake in Kymera Therapeutics in the 4th quarter valued at about $45,000. GF Fund Management CO. LTD. acquired a new stake in Kymera Therapeutics in the 4th quarter valued at about $55,000. Finally, KBC Group NV grew its stake in Kymera Therapeutics by 15.2% in the 1st quarter. KBC Group NV now owns 2,479 shares of the company’s stock valued at $68,000 after acquiring an additional 328 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.